Voyager Therapeutics
LEXINGTON, MA · Founded 2013 · CIK 0001640266 · Biotech · Public
Gene therapy for neurodegenerative diseases targeting tau protein reduction
voyagertherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $119M
- 3 Form D · Jan 2024
- 33 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $60,000,003 | |
| Private capital raised | Form D · SEC | $39,032,821 | |
| Private capital raised | Form D · SEC | $19,999,999 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2286 | CytoDyn Inc. | — | $88M |
| 2287 | Geneoscopy, Inc. | — | $58M |
| 2288 | MarvelBiome, Inc. | — | $55M |
| 2289 | Voyager Therapeutics | — | $119M |
| 2290 | Precision Fermentation, Inc. | — | $53M |
| 2291 | Xencor | — | $46M |
| 2292 | Perceive Biotherapeutics, Inc. | — | $40M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mitchell BloomExecutive Officer
- Todd CarterExecutive Officer
- Grace ColonDirector
- Jacquelyn Fahey SandellExecutive Officer
- James GeraghtyDirector
- Robert HessleinExecutive Officer
- Michael HigginsDirector
- Steven HymanDirector
- Mark LevinDirector
- Catherine MackeyDirector
- Jude OnyiaDirector
- Steven PaulDirector · Executive Officer
- Peter PfreundschuhExecutive Officer
- Glenn PierceDirector
- Alfred SandrockDirector · Executive Officer
- George ScangosDirector
- Robin SwartzExecutive Officer
- Nancy VitaleDirector
Patents
- Tau Binding Compoundsgranted
- Aav Capsids With Increased Tropism To Brain Tissueapplication
- Tau Binding Compoundsgranted
- Compositions And Methods For Regulating Maptapplication
- Compositions And Methods For Treating Amyotrophic Lateral Sclerosis And Disorders Associated With The Spinal Cordapplication
- Redirection Of Tropism Of Aav Capsidsgranted
- Modulatory Polynucleotidesapplication
- Aav Capsid Variants And Uses Thereofapplication
- Aav Capsid Variants And Uses Thereofapplication
- Controlled Expression Of Viral Proteinsapplication
- Aav Capsids With Increased Tropism To Brain Tissuegranted
- Redirection Of Tropism Of Aav Capsidsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.